Last reviewed · How we verify
Polatuzumab
At a glance
| Generic name | Polatuzumab |
|---|---|
| Also known as | Polatuzumab Vedotin, RO5541077, Polivy, Polatuzumab vedotin, DCDS4501S, RG7596 |
| Sponsor | National Cancer Institute (NCI) |
| Target | B-cell antigen receptor complex-associated protein beta chain, Tubulin beta |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Diffuse large B-cell lymphoma refractory
Common side effects
- Peripheral neuropathy
- Nausea
- Fatigue
- Diarrhea
- Constipation
- Alopecia
- Mucositis
- Neutropenia
- Thrombocytopenia
- Anemia
- Pyrexia
- Decreased appetite
Serious adverse events
- Febrile neutropenia
- Pneumonia
- Sepsis
- Fatal adverse reactions
Key clinical trials
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE1)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (PHASE3)
- Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (PHASE2)
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (PHASE1)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polatuzumab CI brief — competitive landscape report
- Polatuzumab updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI